EPISODE · Mar 8, 2024 · 1H 25M
Curaleaf Earnings Review with Boris Jordan and CannaVestments
from Higher Exchanges
This week's show had an all-star cast to review recent earnings. CannaVestments shared his thoughts on the federal and state-level catalysts in 2024 and contrasted this against eroding investor sentiment. He also gave his perspective on the recent results from GTI, Verano, and Trulieve. Boris Jordan, Executive Chairman of Curaleaf, joined the show to review the company's Q4 2023 earnings. He also covered how 280E removal would benefit the business, the results of their recent institutional road show, and thoughts on the rapidly evolving hemp-derived cannabinoids business. If you enjoyed this episode, please leave a five-star review on your favorite podcast platform. It helps new investors find the show and grows the cannabis-investing universe!
Embed this episode
What this episode covers
This week's show had an all-star cast to review recent earnings. CannaVestments shared his thoughts on the federal and state-level catalysts in 2024 and contrasted this against eroding investor sentiment. He also gave his perspective on the recent results from GTI, Verano, and Trulieve. Boris Jordan, Executive Chairman of Curaleaf, joined the show to review the company's Q4 2023 earnings. He also covered how 280E removal would benefit the business, the results of their recent ins...
NOW PLAYING
Curaleaf Earnings Review with Boris Jordan and CannaVestments
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.